Concurrent serious medical illness

Known, clinically suspected, or history of central nervous system (CNS) tumor involvement

Active diarrhea

Known history of coagulation disorder

Patients requiring cytochrome P450 3A4 (CYP3A4) enzyme inducing medications

Requirement for ketoconazole or other strong inhibitor of CYP3A4 enzymes

Prior chemotherapy, immunotherapy, investigational agent, or other therapy used to treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or nitrosoureas) prior to the scheduled administration of EZN-2208

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

What this study is about